BioWorld Asia

Dec. 17, 2003

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld International) Read More

Arpida Moving Iclaprim Into Phase III Trial, Seeking EUR25M

Trial To Test Recombinant Poxvirus Vaccine In Malaria

Genmab Stops HuMax-CD4 Development In Psoriasis

Ingenium Plans Growth After Third Round Brings In EUR13.8M

Benitec Settles ddRNAi Dispute, Raises A$10.9M To Fund Growth

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Novacea Licenses Cancer Drug From KuDOS Pharmaceuticals

London Cluster Growing But Lab Space Shortage Impedes

EU Moving Closer To New Rules On Pharmaceuticals, Tissues, Cells

Industry Representatives Meet In Israel To Discuss Bioengineering

Fulcrum To Help Addex Build Internal Clinical Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...